Every year in biopharma brings its share of grueling defeats, and 2025 was no different, especially for companies targeting ...
The loss of domvanalimab is the latest in a string of high-profile failures recorded across the biopharma world for the TIGIT ...
A study using TIGIT and PD-1 drugs for gastrointestinal disease was canceled for “futility” at an early checkpoint, another ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback